BioPharma Resources

Drug Trial Radar · NCT03537482

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 7, 2018

Primary completion

Sep 15, 2024

Study completion Feb 15, 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
May 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Conditions

  • Hematologic Malignancies

Interventions

  • APG-2575Drug

    APG-2575 will be administered as an oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 28 days

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Duke Unviersity

    Durham, North Carolina · Completed

  • MDACC

    Houston, Texas · Recruiting

  • St. Vincent Hospital

    Fitzroy, Victoria, Australia · Recruiting

  • Epworth Healthcare

    Richmond, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.